Success Story: EB1A Approved in Just 20 Days! Our Firm Assisted a Research Specialist in Securing Success with Direct Premium Processing
Client’s Testimonial:
"I had a very good experience working with Chen Immigration on my EB1A case. Their approach was thoughtful and strategic, with a clear vision for how to present my background in a strong, well-organized, and persuasive way. Thanks to their careful preparation and attention to detail, my case was approved through premium processing without an RFE, and I truly appreciate their professionalism, guidance, and hard work throughout the process.”
On March 19th, 2026, we received another EB-1A (Alien of Extraordinary Ability) approval for a Research Specialist in the Field of Molecular Biology (Approval Notice).
General Field: HMolecular Biology
Position at the Time of Case Filing: Research Specialist
Country of Origin: India
State of Residence at the Time of Filing: Michigan
Approval Notice Date: March 19th, 2026
Processing Time: 20 days (Premium Processing Requested)
Case Summary:
The client’s I-140 EB1A petition was approved based on strong evidence of sustained acclaim and expertise consistent with the extraordinary ability standard. The case presented the client as a molecular biology researcher with a Ph.D. in Poultry Science and over a decade of experience, specializing in immunology, inflammation, and cancer biology, particularly gastrointestinal cancers such as colorectal cancer. The petition highlighted the client’s work on bioactive egg membrane-derived immunomodulators and immune-profiling research.
A key strength of the filing was its focus on impact rather than credentials alone. The petition demonstrated how the client’s research contributed to areas such as cancer signaling pathways, immune-modulating biomaterials, and patient-derived organoid models. It emphasized that the work was not merely academic, but had been used by other researchers in vaccine development, cancer-target discovery, and precision oncology.
The client’s continued engagement in high-level research also supported the case. Current work in cancer-focused research, including studies on pancreatic and colon cancer and therapeutic target identification, showed continuity between past achievements and future contributions, an important factor in EB1A adjudication.
The publication record included 18 peer-reviewed articles and abstracts, supported by citations from researchers in at least 44 countries. Rather than relying on numbers alone, the petition framed these metrics as evidence of global recognition and sustained scholarly contribution. The client’s role as a peer reviewer, with at least 71 completed reviews, further demonstrated recognition within the scientific community.
Additional strength came from evidence of research funding from respected institutions such as the National Institutes of Health and the Crohn’s & Colitis Foundation, indicating independent validation of the work’s significance. Finally, four independent recommendation letters reinforced the objective evidence, highlighting the client’s influence and standing in the field.
We are pleased to have supported this client in achieving approval in just 20 days without any Request for Evidence (RFE).